Advertisement

18F-FDG PET/CT prognostic role in predicting response to salvage therapy in relapsed/refractory Hodgkin's lymphoma

Published:September 24, 2022DOI:https://doi.org/10.1016/j.clinimag.2022.09.004

      Highlights

      • 18F-FDG PET/CT can be used for evaluating salvage therapy candidates diagnosed with relapsed/refractory Hodgkin lymphoma.
      • 18F-FDG PET/CT has the potential to predict each lesion’s response to salvage therapy.
      • SUVmax and MTV≥41% are the most valuable prognostic factors in the initial 18F-FDG PET/CT prior to the salvage therapy.

      Abstract

      Purpose

      To evaluate the response predictors, both clinical and 18F-FDG PET/CT parameters, in Hodgkin's lymphoma (HL) patients diagnosed with refractory/relapsed disease who were planned to receive salvage therapy.

      Methods

      In this retrospective study, all HL patients referred to our center between March 2015 and July 2021 were reviewed. Patients with refractory/relapsed disease who were candidates for salvage therapy were included. 18F-FDG PET/CT measurements at the time of diagnosis were extracted as the predictors, and the lesions' response at the end of the salvage therapy was considered the outcomes. The Kaplan-Meier method and multiple Cox regression were utilized to find the significant parameters to predict the time to reach the complete response. The statistical significance level was set at a two-sided p-value <0.05.

      Results

      A total of 303 tumoral lesions from 64 patients were included. Regarding the factors associated with the response, B symptoms (p-value < 0.01), pathologic subtype (p-value < 0.001), and patient stage (p-value < 0.01) were the significant clinical parameters. In addition, SUVmax (p-value = 0.03), SUVmax/hepatic background SUVmax (p-value = 0.04), SUVmean (in all thresholds; 41% p-value = 0.02, 51% p-value = 0.04, 61% p-value = 0.01), and MTV (in all thresholds; 41% p-value = 0.04, 51% p-value = 0.04, 61% p-value = 0.05) were the significant parameters in the 18F-FDG PET/CT scans. At the median follow-up of 9 months, we found that pathologic subtype (p-value < 0.01), patient stage (p-value = 0.03), SUVmax (p-value = 0.02), SUVmax/hepatic background SUVmax (p-value = 0.03), SUVmean (in all thresholds; 41% p-value = 0.01, 51% p-value = 0.02, 61% p-value = 0.02), and MTV ≥ 41% (p-value = 0.02) were significant predictive factors. Multiple Cox regression showed the pathologic subtype (p-value = 0.02), SUVmax (p-value = 0.02), and MTV ≥ 41% (p-value = 0.04) were the most significant predictors.

      Conclusion

      Our study demonstrated that by knowing the histopathology of the lesions, the pre-treatment 18F-FDG PET/CT might be able to predict response after salvage therapy in the relapsed/refractory HL.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Shanbhag S.
        • Hodgkin Ambinder R.F.
        Lymphoma: a review and update on recent progress.
        CA Cancer J Clin. 2018; 68: 116-132
        • Küppers R.
        The biology of Hodgkin's lymphoma.
        Nat Rev Cancer. 2009; 9: 15-27
        • Swerdlow S.H.
        • Campo E.
        • Pileri S.A.
        • et al.
        The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
        Blood. 2016; 127: 2375-2390
        • Ansell S.M.
        Hodgkin Lymphoma: Diagnosis and Treatment. Elsevier, 2015: 1574-1583
        • Jhanwar Y.S.
        • Straus D.J.
        The role of PET in lymphoma.
        J Nucl Med. 2006; 47: 1326-1334
        • Cronin C.G.
        • Swords R.
        • Truong M.T.
        • et al.
        Clinical utility of PET/CT in lymphoma.
        Am J Roentgenol. 2010; 194: W91-W103
        • Weiler-Sagie M.
        • Bushelev O.
        • Epelbaum R.
        • et al.
        18F-FDG avidity in lymphoma readdressed: a study of 766 patients.
        J Nucl Med. 2010; 51: 25-30
        • Baba S.
        • Abe K.
        • Isoda T.
        • Maruoka Y.
        • Sasaki M.
        • Honda H.
        Impact of FDG-PET/CT in the management of lymphoma.
        Ann Nucl Med. 2011; 25: 701-716
        • Paes F.M.
        • Kalkanis D.G.
        • Sideras P.A.
        • Serafini A.N.
        FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease.
        Radiographics. 2010; 30: 269-291
        • El-Galaly T.C.
        • Villa D.
        • Gormsen L.C.
        • Baech J.
        • Lo A.
        • Cheah C.Y.
        FDG-PET/CT in the management of lymphomas: current status and future directions.
        J Intern Med. 2018; 284: 358-376
        • Johnson S.A.
        • Kumar A.
        • Matasar M.J.
        • Schöder H.
        • Rademaker J.
        Imaging for staging and response assessment in lymphoma.
        Radiology. 2015; 276: 323-338
        • Cheson B.D.
        • Fisher R.I.
        • Barrington S.F.
        • et al.
        Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
        J Clin Oncol. 2014; 32: 3059
        • Barrington S.F.
        • Mikhaeel N.G.
        • Kostakoglu L.
        Roleof imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
        Journal of clinical oncology. 2014; 32: 3048
        • Mottok A.
        • Steidl C.
        Biology of classical hodgkin lymphoma: implications for prognosis and novel therapies.
        Blood. 2018; 131: 1654-1665
        • Lue K.-H.
        • Wu Y.-F.
        • Liu S.-H.
        • et al.
        Prognostic value of pretreatment radiomic features of 18F-FDG PET in patients with Hodgkin lymphoma.
        Clin Nucl Med. 2019; 44: e559-e565
        • Guo B.
        • Tan X.
        • Ke Q.
        • Cen H.
        Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis.
        PloS one. 2019; 14e0210224
        • Milgrom S.A.
        • Elhalawani H.
        • Lee J.
        • et al.
        A PET radiomics model to predict refractory mediastinal Hodgkin lymphoma.
        Sci Rep. 2019; 9: 1-8
        • Moskowitz A.J.
        • Schöder H.
        • Gavane S.
        • et al.
        Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
        Blood. 2017; 130: 2196-2203
        • Zaucha J.M.
        • Chauvie S.
        • Zaucha R.
        • Biggii A.
        • Gallamini A.
        The role of PET/CT in the modern treatment of Hodgkin lymphoma.
        Cancer Treat Rev. 2019; 77: 44-56
        • Esfahani S.A.
        • Heidari P.
        • Halpern E.F.
        • Hochberg E.P.
        • Palmer E.L.
        • Mahmood U.
        Baseline total lesion glycolysis measured with 18F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study.
        Am J Nucl Med Molec Imaging. 2013; 3: 272
        • Ryu I.S.
        • Kim J.S.
        • Roh J.-L.
        • et al.
        Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
        J Nucl Med. 2013; 54: 1032-1038
        • Dibble E.H.
        • Alvarez A.C.L.
        • Truong M.-T.
        • Mercier G.
        • Cook E.F.
        • Subramaniam R.M.
        18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging.
        J Nucl Med. 2012; 53: 709-715
        • Adams H.J.
        • Kwee T.C.
        Prognostic value of pretransplant FDG-PET in refractory/relapsed hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
        Ann Hematol. 2016; 95: 695-706
        • Markova J.
        • Kobe C.
        • Skopalova M.
        • et al.
        FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value.
        Ann Oncol. 2009; 20: 1270-1274https://doi.org/10.1093/annonc/mdn768
        • Spaepen K.
        • Stroobants S.
        • Dupont P.
        • et al.
        Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.
        Blood. 2003; 102: 53-59
        • Akhtar S.
        • Al-Sugair A.S.
        • Abouzied M.
        • et al.
        Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
        Bone Marrow Transplant. 2013; 48: 1530-1536https://doi.org/10.1038/bmt.2013.88
        • Hutchings M.
        FDG-PET response-adapted therapy: Is 18f-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy? Review.
        Hematol Oncol Clin North Am. 2014; 28: 87-103https://doi.org/10.1016/j.hoc.2013.10.008
        • Moskowitz C.H.
        • Matasar M.J.
        • Zelenetz A.D.
        • et al.
        Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with hodgkin lymphoma.
        Blood. 2012; 119: 1665-1670https://doi.org/10.1182/blood-2011-10-388058
        • Smeltzer J.P.
        • Cashen A.F.
        • Zhang Q.
        • et al.
        Prognostic significance of FDG-PET in relapsed or refractory classical hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
        Biol Blood Marrow Transplant. 2011; 17: 1646-1652https://doi.org/10.1016/j.bbmt.2011.04.011
        • Albano D.
        • Mazzoletti A.
        • Spallino M.
        • et al.
        Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients.
        Ann Hematol. 2020; 99: 1321-1330https://doi.org/10.1007/s00277-020-04039-w
        • Allen P.B.
        • Gordon L.I.
        Frontline therapy for classical hodgkin lymphoma by stage and prognostic factors. Review.
        Clin Med Insights: Oncol. 2017; : 11https://doi.org/10.1177/1179554917731072
        • Annunziata S.
        • Cuccaro A.
        • Calcagni M.L.
        • Hohaus S.
        • Giordano A.
        • Rufini V.
        Interim FDG-PET/CT in hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET).
        Ann Nucl Med. 2016; 30: 588-592https://doi.org/10.1007/s12149-016-1092-9
        • Ben Bouallègue F.
        • Tabaa Y.A.
        • Kafrouni M.
        • Cartron G.
        • Vauchot F.
        • Mariano-Goulart D.
        Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas.
        Med Phys. 2017; 44: 4608-4619https://doi.org/10.1002/mp.12349
        • Agostinelli C.
        • Gallamini A.
        • Stracqualursi L.
        • et al.
        The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, european, multicentre cohort study.
        Lancet Haematol. 2016; 3: e467-e479https://doi.org/10.1016/S2352-3026(16)30108-9
        • Kluge R.
        • Wittig T.
        • Georgi T.W.
        • et al.
        Comparison of interim PET response to second-line versus first-line treatment in classic hodgkin lymphoma: contribution to the development of response criteria for relapsed or progressive disease.
        J Nucl Med. 2021; 62: 338-341https://doi.org/10.2967/jnumed.120.247924
        • Moskowitz A.J.
        • Schöder H.
        • Yahalom J.
        • et al.
        PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
        Lancet Oncol. 2015; 16: 284-292https://doi.org/10.1016/S1470-2045(15)70013-6
        • Angelopoulou M.K.
        • Mosa E.
        • Pangalis G.A.
        • et al.
        The significance of PET/CT in the initial staging of hodgkin lymphoma: experience outside clinical trials.
        Anticancer Res. 2017; 37: 5727-5736https://doi.org/10.21873/anticanres.12011
        • Akhtari M.
        • Milgrom S.A.
        • Pinnix C.C.
        • et al.
        Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation.
        Blood. 2018; 131: 84-94
        • Mettler J.
        • Müller H.
        • Voltin C.-A.
        • et al.
        Metabolic tumor volume for response prediction in advanced-stage Hodgkin lymphoma.
        J Nucl Med. 2019; 60: 207-211
        • Cottereau A.-S.
        • Versari A.
        • Loft A.
        • et al.
        Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.
        Blood. 2018; 131: 1456-1463
        • Meignan M.
        • Sasanelli M.
        • Casasnovas R.O.
        • et al.
        Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients.
        Eur J Nucl Med Mol Imaging. 2014; 41: 1113-1122
        • Boellaard R.
        • O’Doherty M.J.
        • Weber W.A.
        • et al.
        FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.
        Eur J Nucl Med Mol Imaging. 2010; 37: 181-200
        • Ozuah N.W.
        • LaCasce A.S.
        How to approach a patient with limited stage hodgkin lymphoma who remains PET positive at the end of chemotherapy: radiation Therapy?Review.
        Clin Lymphoma Myeloma Leukemia. 2017; 17: 710-715https://doi.org/10.1016/j.clml.2017.06.019
        • Van Heertum R.L.
        • Scarimbolo R.
        • Wolodzko J.G.
        • et al.
        Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.
        Drug Des Dev Ther. 2017; 11: 1719-1728https://doi.org/10.2147/DDDT.S136988
        • Tawfik M.M.H.
        • Monib A.M.
        • Yassin A.
        • Ali S.A.
        Comparison between RECIST and PERCIST criteria in therapeutic response assessment in cases of lymphoma.
        Egypt J Radiol Nucl Med. 2020; 51: 1-10
        • Joo Hyun O.
        • Lodge M.A.
        • Wahl R.L.
        Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0.
        Radiology. 2016; 280: 576